Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

NEXT STORY
Predictive Oncology: Helomics to present initial findings from its analysis of UK 100,000 Genomes Project data towards its goal of building AI-driven predictive models of ovarian cancer
PREV STORY
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal ...

author_avatar
NASDAQ Market News

Cancer Genetics, Inc. to Present Insights on Patient Stratification & Diagnostics for Immunotherapy Trials at the Companion Diagnostics (CDx) Symposium on November 2-3

The CDx market is expected to reach six billion US dollars by 2022 and ...

author_avatar
NASDAQ Market News

Taconic Biosciences Expands Production of Critical Immunodeficient Model

author_avatar
NASDAQ Market News